LRP1: A Potential Drug Target for Cardiovascular Disease (G4035)

Target Name: LRP1

NCBI ID: G4035

LRP1

LRP1: A Potential Drug Target for Cardiovascular Disease

Low density lipoprotein-related protein 1 (LRP1) is a protein that is expressed in various tissues throughout the body, including the liver, heart, and blood vessels. It is a member of the Lipoprotein Receptor Subfamily (LRP) and is characterized by its ability to interact with low density lipoprotein (LDL) cholesterol.

LRP1 is a potential drug target and has been identified as a potential biomarker for the development of cardiovascular disease. Studies have shown that LRP1 is involved in the regulation of cellular processes that are important for the development and progression of cardiovascular disease, including the regulation of inflammation, fibrosis, and cellular stress.

One of the key functions of LRP1 is its role in the regulation of cellular inflammation. LRP1 has been shown to play a key role in the regulation of the production and activation of immune cells, including T cells and macrophages. It is also involved in the regulation of the production of pro-inflammatory cytokines, such as TNF-alpha and IL-18.

In addition to its role in inflammation, LRP1 is also involved in the regulation of cellular stress and fibrosis. LRP1 has been shown to play a key role in the regulation of cellular stress responses, including the regulation of cell death and the regulation of cell cycle progression. It is also involved in the regulation of the production of extracellular matrix (ECM) components, such as collagen, which are involved in fibrosis.

LRP1 is also involved in the regulation of cellular signaling pathways that are important for the development and progression of cardiovascular disease. It is a positive regulator of the PI3K/Akt signaling pathway, which is involved in the regulation of cellular signaling pathways that are important for the development and progression of cardiovascular disease.

In conclusion, LRP1 is a protein that is involved in a number of important cellular processes that are important for the development and progression of cardiovascular disease. As a potential drug target and biomarker, LRP1 is a promising target for the development of new treatments for cardiovascular disease. Further research is needed to fully understand the role of LRP1 in the development and progression of cardiovascular disease, and to develop effective therapies that target this protein.

Protein Name: LDL Receptor Related Protein 1

Functions: Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells (PubMed:11907044, PubMed:12713657). Required for early embryonic development (By similarity). Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. Acts as an LRPAP1 alpha-2-macroglobulin receptor (PubMed:26142438, PubMed:1702392). Acts as TAU/MAPT receptor and controls the endocytosis of TAU/MAPT as well as its subsequent spread (PubMed:32296178). May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission (PubMed:12888553)

The "LRP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets